Impact of donor-recipient age on cardiac transplant survival. Subanalysis of the Spanish Heart Transplant Registry.

Combinaciones de edad de donante y receptor Donor age Donor/recipient age combinations Edad del donante Edad del receptor Heart transplant Recipient age Supervivencia Survival Trasplante cardiaco

Journal

Revista espanola de cardiologia (English ed.)
ISSN: 1885-5857
Titre abrégé: Rev Esp Cardiol (Engl Ed)
Pays: Spain
ID NLM: 101587954

Informations de publication

Date de publication:
May 2021
Historique:
received: 03 10 2019
accepted: 21 02 2020
pubmed: 1 7 2020
medline: 15 5 2021
entrez: 1 7 2020
Statut: ppublish

Résumé

The age of heart transplant recipients and donors is progressively increasing. It is likely that not all donor-recipient age combinations have the same impact on mortality. The objective of this work was to compare survival in transplant recipients according to donor-recipient age combinations. We performed a retrospective analysis of transplants performed between 1 January 1993 and 31 December 2017 in the Spanish Heart Transplant Registry. Pediatric transplants, retransplants and combined transplants were excluded (6505 transplants included). Four groups were considered: a) donor <50 years for recipient <65 years; b) donor <50 years for recipient ≥ 65 years; c) donor ≥ 50 years for recipient ≥ 65 years, and d) donor ≥ 50 years for recipient <65 years. The most frequent group was young donor for young recipient (73%). There were differences in the median survival between the groups (P <.001): a) younger-younger: 12.1 years, 95%CI, 11.5-12.6; b) younger-older: 9.1 years, 95%CI, 8.0-10.5; c) older-older: 7.5 years, 95%CI, 2.8-11.0; d) older-younger: 10.5 years, 95%CI, 9.6-12.1. On multivariate analysis, independent predictors of mortality were the age of the donor and the recipient (0.008 and 0.001, respectively). The worst combinations were older-older vs younger-younger (HR, 1.57; 95%CI, 1.22-2.01; P <.001) and younger-older vs younger-younger (HR, 1.33; 95%CI, 1.12-1.58; P=.001). Age (of the donor and recipient) is a relevant prognostic factor in heart transplant. The donor-recipient age combination has prognostic implications that should be identified when accepting an organ for transplant.

Identifiants

pubmed: 32600994
pii: S1885-5857(20)30222-X
doi: 10.1016/j.rec.2020.02.016
pii:
doi:

Types de publication

Journal Article

Langues

eng spa

Sous-ensembles de citation

IM

Pagination

393-401

Informations de copyright

Copyright © 2020 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Auteurs

Raquel López-Vilella (R)

Unidad de Insuficiencia Cardiaca y Trasplante, Servicio de Cardiología, Hospital Universitario y Politécnico La Fe, Valencia, Spain. Electronic address: lopez_raqvil@gva.es.

Francisco González-Vílchez (F)

Servicio de Cardiología, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain.

María G Crespo-Leiro (MG)

Servicio de Cardiología, Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares, CIBERCV, A Coruña, Spain; Instituto de Investigación Biomédico A Coruña (INIBIC), A Coruña, Spain; Universidade da Coruña (UDC), A Coruña, Spain.

Javier Segovia-Cubero (J)

Servicio de Cardiología, Hospital Universitario Puerta de Hierro de Majadahonda, Majadahonda, Madrid, Spain.

Manuel Cobo (M)

Servicio de Cardiología, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain.

Juan Delgado-Jiménez (J)

Servicio de Cardiología, Hospital Universitario 12 de Octubre, Madrid, Spain; Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares, CIBERCV, Madrid, Spain.

José María Arizón Del Prado (JM)

Servicio de Cardiología, Hospital Universitario Reina Sofía, Córdoba, Spain.

Manuel Martínez-Sellés (M)

Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares, CIBERCV, Madrid, Spain; Servicio de Cardiología, Hospital Universitario Gregorio Marañón, Madrid, Spain; Universidad Europea de Madrid, Madrid, Spain.

José Manuel Sobrino Márquez (JM)

Servicio de Cardiología, Hospital Universitario Virgen del Rocío, Sevilla, Spain.

Sonia Mirabet-Pérez (S)

Servicio de Cardiología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

José González-Costello (J)

Servicio de Cardiología, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

Félix Pérez-Villa (F)

Servicio de Cardiología, Hospital Clínic y Provincial de Barcelona, Barcelona, Spain.

José Luis Lambert-Rodríguez (JL)

Servicio de Cardiología, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain.

Gregorio Rábago-Aracil (G)

Servicio de Cardiología, Clínica Universitaria de Navarra, Pamplona, Navarra, Spain.

María Teresa Blasco-Peiró (MT)

Servicio de Cardiología, Hospital Universitario Miguel Servet, Zaragoza, Spain.

Luis de la Fuente-Galán (L)

Servicio de Cardiología, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.

Iris Garrido-Bravo (I)

Servicio de Cardiología, Hospital Virgen de la Arrixaca, El Palmar, Murcia, Spain.

Déborah Otero (D)

Instituto de Investigación Biomédico A Coruña (INIBIC), A Coruña, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares, CIBERCV, A Coruña, Spain; Universidade da Coruña (UDC), A Coruña, Spain; Instituto Universitario de Ciencias de la Salud, A Coruña, Spain.

Luis Almenar-Bonet (L)

Unidad de Insuficiencia Cardiaca y Trasplante, Servicio de Cardiología, Hospital Universitario y Politécnico La Fe, Valencia, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares, CIBERCV, Madrid, Spain; Facultad de Medicina, Universitat de València, Valencia, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH